ImmusanT is a clinical development-stage biotechnology company focused on an innovative disease-modifying approach to induce immune tolerance in autoimmune diseases. Using our proprietary discovery platform for targeted (epitope-specific) immunotherapy, ImmusanT is developing a therapy and personalized diagnostics for celiac disease and is expanding to other autoimmune diseases including Type 1 diabetes.
We are now recruiting for clinical trials in celiac disease.
November 14, 2017
Immusant Raises $40 Million in Series C Financing
One Kendall Square
Cambridge, MA 02139